Array Biopharma (NASDAQ: ARRY) reported Q1 EPS of ($0.22), in-line with the analyst estimate of ($0.22). Revenue for the quarter came in at $29.7 million versus the consensus estimate of $33.28 million.

For earnings history and earnings-related data on Array Biopharma (ARRY) click here.